<?xml version="1.0" encoding="UTF-8"?>
<p>Viral hepatitis is a ubiquitous infectious disease. In 2015, an estimated 257 million persons had active HBV infection (
 <xref rid="R1" ref-type="bibr">
  <italic>1</italic>
 </xref>), 71 million persons had active HCV (
 <xref rid="R2" ref-type="bibr">
  <italic>2</italic>
 </xref>) infection, and approximately 1.3 million died from viral hepatitis and resulting liver disease (
 <xref rid="R1" ref-type="bibr">
  <italic>1</italic>
 </xref>). Despite the availability of hepatitis B vaccines and treatment for hepatitis B and C, few low- and middle-income countries have sustainable and scalable elimination programs. Lack of financing for large-scale testing and treatment is the main barrier to elimination, despite evidence of a positive return on investment (
 <xref rid="R3" ref-type="bibr">
  <italic>3</italic>
 </xref>). Certain countries require innovative approaches to financing because traditional funding mechanisms, such as donations and grants, remain largely unavailable for hepatitis elimination programs (
 <xref rid="R4" ref-type="bibr">
  <italic>4</italic>
 </xref>).
</p>
